Preloaded Autoinjector | BPC-157 | 3ml Pen | 5mg/ml

The BPC-157 autoinjector is a preloaded 3ml research device containing BPC-157 in solution at 5mg/ml, giving 15mg of total peptide. BPC-157 is a fifteen-residue partial sequence of a protein identified in human gastric juice, CAS 137525-51-0, molecular weight 1419.55, and its sequence composition makes it comparatively well-supported in solution.

Specification Table

What Does the Sequence Tell You?

Reading Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val predicts a good deal about how this peptide behaves, and it is worth doing before considering any pharmacology.

Four prolines, three of them consecutive at positions 3, 4 and 5. Proline restricts backbone rotation severely, so a run of three imposes a rigid, extended local conformation rather than allowing the flexible chain most short peptides adopt. That rigidity contributes to proteolytic resistance, since many peptidases require the substrate to adopt a particular conformation in the active site.

No cysteine. No disulfide bonds to form, scramble or reduce, which removes the single largest source of preparation ambiguity affecting growth factors and longer peptides.

None of the five oxidation-prone residues. No methionine, tryptophan, tyrosine or histidine, so metal-catalysed and photo-oxidation routes are largely closed.

Two adjacent aspartates at positions 10 and 11, followed by alanine. Asp-Gly sequences are the classic isomerisation risk; Asp-Asp-Ala is less problematic but aspartate isomerisation remains the most plausible chemical degradation route for this sequence in solution.

What Is the VEGFR2 Association?

Hsieh and colleagues provided the clearest mechanistic characterisation available for this compound (Hsieh et al., Journal of Molecular Medicine, 2017).

In human vascular endothelial cells they reported that BPC-157 increased both mRNA and protein expression of VEGFR2, the principal receptor mediating vascular endothelial growth factor signalling, without increasing VEGF-A itself. That distinction matters: the compound appears to act on receptor availability rather than on ligand supply.

They further reported that BPC-157 promoted VEGFR2 internalisation and produced time-dependent activation of the VEGFR2-Akt-eNOS signalling axis. Endothelial nitric oxide synthase sits at the end of that chain, which links the pathway to nitric oxide production and vascular tone.

Vessel density increased in vivo and in vitro in the same body of work, and recovery of blood flow was accelerated in a rat hind-limb ischaemia model.

What this does not establish is a receptor for BPC-157 itself. No direct binding partner has been identified, and the compound is described as acting on VEGFR2 expression and trafficking rather than as a VEGFR2 ligand. That gap is real and is worth stating.

How Does the BPC-157 Autoinjector Compare With a Vial?

For the BPC-157 autoinjector the comparison turns on the same trade-off as every device in this catalogue, though the balance here is more favourable than most.

The device removes reconstitution and its associated failure modes: diluent measurement error, incomplete dissolution, shear from over-agitation, adsorptive loss during transfer, and variable time between preparation and use.

It accepts solution-state storage in exchange. For BPC-157 that exchange is comparatively cheap, because the sequence carries no oxidation-prone residues and no disulfides, leaving aspartate isomerisation and slow amide hydrolysis as the principal routes. Both proceed considerably more slowly at 2-8°C than oxidation would in a methionine-containing peptide.

At 5 mg/ml the solution is approximately 3.5 millimolar, which suits cell-based work with modest dilution. Published in vitro concentrations for this compound span a wide range in the literature, so the appropriate dilution depends on which body of work a design is following.

What Is Not Established About This Compound?

A good deal, and the gaps are worth naming because BPC-157 attracts more confident description than its evidence supports.

No receptor has been identified. The VEGFR2 association concerns expression and trafficking rather than direct binding, and no protein has been shown to bind BPC-157 with the affinity and specificity a receptor implies.

No human clinical trial has been completed and published. Sikiric and colleagues reference tolerability in early inflammatory bowel disease work, but there is no phase III dataset and no approved formulation anywhere.

Pharmacokinetics are poorly characterised. Half-life figures circulate widely without traceable primary sources, and for a fifteen-residue peptide with no protective modifications beyond its proline content, rapid clearance would be the default expectation.

Solution stability over device shelf life is unpublished for this format specifically, which is the gap most relevant to anyone using this product rather than the compound generally.

How Should BPC-157 Findings Be Interpreted?

This compound attracts unusually confident description, and a page that repeats it without qualification will not survive scrutiny from anyone who has read the primary literature.

The published record is substantial in volume and narrow in provenance. A large proportion of the animal work comes from one research group in Croatia, spanning tendon, muscle, gastrointestinal and vascular models over more than two decades. The work is detailed. Independent replication by unaffiliated laboratories is thinner than the citation count suggests.

Effect sizes reported in that literature are frequently large, and large effects across many unrelated tissue systems from a single compound warrant more scepticism than they usually receive. A molecule that improves every model it is tested in is either remarkable or is being tested in a way that favours it.

None of that means the findings are wrong. It means a researcher designing around them should build in the controls that would detect a false positive: blinded assessment, pre-registered endpoints, and where possible a comparator with known activity.

The absence of an identified receptor compounds the issue, because without a molecular target there is no mechanistic prediction to test against. An effect with no mechanism is harder to falsify, which is a weakness rather than a strength.

What Would Strengthen the Evidence Base?

For the BPC-157 autoinjector, naming what is missing is more useful than restating what exists, and for this compound the gaps are specific.

Independent replication of the principal animal findings by laboratories with no connection to the originating group would address the provenance concentration directly. Several findings have never been reproduced outside that lineage.

Identification of a molecular target would convert a descriptive literature into a mechanistic one. Affinity chromatography, photoaffinity labelling and proteomic pulldown approaches have all been applied successfully to comparable orphan peptides.

Pharmacokinetic characterisation would give exposure figures that designs could work from rather than around. No reliable half-life exists, which makes translating between in vitro and in vivo work guesswork.

Blinded, pre-registered animal work would address the effect-size question. Where a compound reports large advantages across many unrelated models, blinding is the control that distinguishes a real broad-spectrum effect from an assessment artefact.

Verifying and Handling the Device

Inspect the solution before each draw against both light and dark backgrounds. It should be clear and free of particulate. A colourless peptide solution provides no colour cue, so clarity is the only visual signal available.

Verify delivered volume gravimetrically at least once per device. Actuate onto a tared vessel, record the mass, convert using solution density, repeat across several actuations. Run the check at the temperature of intended use, since cold solution is more viscous and viscosity affects delivery in a spring mechanism.

Discard rather than measure the first actuation after any rest period. Both air ingress and seal relaxation produce under-delivery on the first use after standing.

Keep it at 2-8°C shielded from light, and return the device to packaging whenever it is not in use. Record lot, date of first actuation, storage conditions and volume drawn per session, since the interval between first use and each later draw is an experimental variable while shelf-life data remains unpublished.

A Note on Concentration Selection

Published in vitro concentrations for the BPC-157 autoinjector compound span an unusually wide range, and picking one requires knowing which body of work a design is following.

That spread is itself informative. A compound with a well-characterised target usually converges on a concentration range across laboratories. Wide dispersion suggests either genuine system dependence or insufficient standardisation, and for BPC-157 the absence of an identified receptor makes the second harder to rule out.

The practical response is to run a concentration-response curve rather than adopting a single figure from a paper using a different system.

Where a design must use one concentration, state which published work it follows and why, so a reader can locate the choice in the literature rather than treating it as arbitrary.

What Does the Preclinical Record Actually Report?

The rodent literature on this synthetic peptide is large, consistent within itself, and produced almost entirely by one research group, which is the combination a reader has to hold in mind throughout.

The compound is a stable fragment of a gastric protein, 15 amino acids long, and the reported work centres on injury models rather than on healthy animals.

Tendon models are the most cited. Reported effects on tendon fibroblasts include increased cell migration and altered collagen synthesis in culture, with the cell migration result the one most often reproduced.

Ligament and muscle injury models appear alongside them, with the ligament work following the same pattern of accelerated closure against untreated controls.

Angiogenesis is the mechanistic thread running through most of it, with reported blood vessel formation attributed to VEGFR2 signalling and downstream nitric oxide pathways.

Increased growth hormone receptor expression in tendon fibroblasts is reported in one of those papers, which is the closest the record comes to a named receptor-level effect.

Gastrointestinal models make up the other large group, including work in colitis-like injury, which is where the gut health language attached to this compound originates.

Two things about that body of work deserve stating rather than glossing.

Independent replication outside the originating group is thin, and no adequately powered human trial of this compound exists in any indication.

So tissue repair and tissue regeneration are descriptions of rodent findings here, not of anything demonstrated in a person.

Claims that it can reduce inflammation, resolve joint pain or accelerate muscle recovery do not have human evidence behind them, and this product is not offered for any of those purposes.

What Is the Wolverine Stack, and Is This Product Part of It?

Search traffic for this compound is dominated by one phrase, and it is worth addressing directly rather than pretending it does not exist.

The wolverine stack is a market nickname for combining this peptide with thymosin beta-4, usually sold as TB-500, on the reasoning that two compounds with reported tissue repair activity should work better together.

Sometimes GHK-Cu or KPV joins the combination, and the whole thing is marketed for injury recovery, joint recovery, chronic pain, a muscle strain and soft tissue repair alike.

No controlled study has tested that combination in anything. The wolverine stack is a marketing construct rather than a protocol with evidence, and the name comes from a comic-book character rather than from a laboratory.

The same grouping is sold as healing peptides, and this compound specifically is sometimes called the wolverine peptide, which is the same claim compressed into one word.

A wolverine stack listing tells a buyer what two vendors decided to sell together. It says nothing about whether either compound does anything, and it is not a delivery method or a protocol.

Growth hormone secretagogues such as ipamorelin, and GLP-1 drugs such as semaglutide, turn up in the same stack guides despite sharing no mechanism with this peptide at all.

Regenerative medicine as a field does contain real interventions, PRP among them, that have been through actual trials with mixed results. A peptide stack assembled from vendor listings is not in that category.

Anyone comparing this against PRP or stem cell therapy is comparing an unapproved research chemical against clinical procedures, which is not a like-for-like comparison.

None of that makes the wolverine stack a fraud. It makes it an untested idea sold as a finished one, and the distinction matters to anyone deciding what to buy.

What Is the Regulatory and Anti-Doping Position?

Two separate regulatory facts attach to this compound and they are often confused with each other.

The first is that it holds no approval anywhere. It is not an FDA-approved drug, and in 2023 the FDA placed it in the category of substances that present significant safety risks for compounding, which removed it from the Section 503A bulks list.

That means a compounding pharmacy in the United States cannot lawfully compound it for patients, which is a specific change and one that a lot of listings have not caught up with.

The second is anti-doping. WADA, the World Anti-Doping Agency, prohibits this compound. It appears on the prohibited list under the growth factor and peptide categories, in and out of competition.

Any athlete subject to testing who uses it is committing an anti-doping rule violation, and that is true regardless of the delivery format or the label on the container.

Stating that plainly is more useful than leaving it for somebody to discover afterwards.

This device is supplied for laboratory research only. It is not a peptide therapy, not a treatment, and not for administration to humans or animals.

What Is Known About the Safety Profile?

Very little, and the shape of that gap is worth describing precisely rather than summarising as reassurance.

The rodent work reports no obvious toxicity across a wide range of doses, which is where the safety profile claims circulating for this compound come from.

Rodent tolerability at short duration is not a human safety profile. No trial has characterised side effects in people, and no long-term data exists in any species.

The routes used in that published work were mostly intraperitoneal and intragastric. The market uses subcutaneous and intramuscular administration instead, so even the animal safety data does not describe the route the market has adopted.

Where injection is discussed for this compound, the reported problems are local: injection site reactions, tenderness and irritation at the injection site, which are common to any subcutaneous injection of an unbuffered peptide solution.

An intramuscular injection carries the same local considerations and no additional evidence.

The theoretical concern that gets least attention is the mechanism itself. A compound promoting angiogenesis is promoting blood vessel formation indiscriminately, and no study has examined what that does over time in a person with an undiagnosed tumour.

That is a hypothesis rather than a finding, and it is the reason the absence of long-term human data matters more here than it would for an inert compound.

Anti-inflammatory effects reported in the gut models, including reduced inflammatory cytokines in colitis-like injury, are the basis of leaky gut and ulcerative colitis claims made by sellers. Neither condition has been studied with this compound in a controlled human trial.

Biohackers running a peptide protocol on themselves are not generating that evidence either, since an uncontrolled self-experiment cannot separate an effect from the natural course of an injury.

How Does the Device Compare With Other Formats?

This compound is sold in several presentations and the differences between them are practical rather than chemical.

The most common is a lyophilized powder in a vial. Buyers reconstitute peptides of that kind with bacteriostatic water before use, and that step is where most handling error enters. It is the step this format removes.

Removing it changes the arithmetic and nothing else. A peptide injection prepared from a device and one prepared from a vial deliver the same molecule with the same absence of human evidence behind it.

Capsules also circulate, marketed on the argument that the peptide survives stomach acid. That claim is contested and the oral bioavailability data behind it is thin.

A nasal spray version exists in the same market and carries the same absence of published pharmacokinetic data by that route.

What no format changes is the evidence. A preloaded device and a vial contain the same molecule and the same amount of published human data, which is none.

Certificates matter more than format. Ask for HPLC purity with the gradient stated, mass confirmation, and endotoxin testing, since a solution-state product in a device cannot be re-analysed by the buyer before use.

Endotoxins are the specific concern a purity figure misses. A preparation can be 99 percent pure by HPLC and still carry bacterial endotoxins from synthesis or filling, and only a dedicated assay detects them.

Third-party testing and published COAs are the distinguishing feature between careful suppliers and the rest, and the impurities question is the one a purity percentage alone does not answer.

Published Literature

Validated against publisher records or primary indexes. The 2017 paper is the source for the VEGFR2 findings described in the mechanism section.

1. Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VH, Pang JS. Journal of Molecular Medicine. 2017;95(3):323-333. DOI: 10.1007/s00109-016-1488-y
2. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. Journal of Applied Physiology. 2011;110(3):774-780. PMID: 21030672
3. Sikiric P, Seiwerth S, Rucman R, et al. Current Pharmaceutical Design. 2011;17(16):1612-1632. PMID: 21548867
4. Huang T, Zhang K, Sun L, Xue X, Zhang C, Shu Z, Mu N, Gu J, Zhang W, Wang Y, Zhang Y, Zhang W. Drug Design, Development and Therapy. 2015;9:2485-2499.
5. Chang CH, Tsai WC, Hsu YH, Pang JH. Molecules. 2014;19(11):19066-19077.

Frequently Asked Questions